OR WAIT null SECS
6 Endocrinology Headlines You May Have Missed in July 2025
Discover key advancements in endocrinology from July 2025, including FDA approvals and trial results.
With mounting momentum across endocrine subfields, July 2025 delivered a mix of pipeline developments, regulatory decisions, and major trial readouts underscoring the rapid evolution of care in diabetes, growth hormone deficiency, and chronic kidney disease (CKD).
In this month’s endocrinology update, we spotlight the most clinically relevant stories from July, including a phase 2 win for rilparencel in CKD and diabetes, US Food and Drug Administration (FDA) approval of lonapegsomatropin (Skytrofa) for adult growth hormone deficiency, and landmark cardiovascular data for tirzepatide (Mounjaro) from the SURPASS-CVOT trial.
This recap also features data highlights from ENDO 2025, including 3-year findings on palopegteriparatide in hypoparathyroidism, new insights into hypercortisolism in treatment-resistant type 2 diabetes, and a fresh episode of Diabetes Dialogue recapping the meeting’s most talked-about moments from GLP-1s and SGLT2s to the arrival of “Diabetes Barbie.”
Endocrinology Pipeline Updates in July 2025
Rilparencel Improves eGFR Slope in Phase 2 CKD, Diabetes REGEN-007 Trial
On July 8, 2025, ProKidney Corp announced positive topline phase 2 REGEN-007 trial results for rilparencel in patients with chronic kidney disease (CKD) and diabetes. Based on data from the Group 1 mITT population, 2 scheduled kidney injections reduced the annual eGFR slope decline by 78%, from –5.8 to –1.3 mL/min/1.73 m², with statistical and clinical significance (P < .001), and showed potential dose response in Group 2. According to ProKidney, the findings support the design of the ongoing phase 3 PROACT 1 trial and may enable accelerated approval using eGFR slope as a surrogate endpoint.
On July 28, 2025, Ascendis Pharma announced US Food and Drug Administration approval of lonapegsomatropin-tcgd for replacement of endogenous growth hormone in adults with growth hormone deficiency. Based on results from the phase 3 foresiGHt trial in 259 adults, weekly lonapegsomatropin achieved superiority over placebo in reducing trunk fat and increasing lean body mass at week 38, with a safety profile comparable to daily somatropin. According to Ascendis Pharma, the approval addresses a longstanding unmet need in adult growth hormone deficiency and offers a less burdensome once-weekly regimen that may improve adherence and outcomes.
SURPASS-CVOT: Tirzepatide Bests Dulaglutide for Cardiovascular Protection
On July 31, 2025, Eli Lilly and Company announced topline results from the phase 3 SURPASS‑CVOT trial comparing tirzepatide to dulaglutide (Trulicity) in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Based on outcome data, tirzepatide met the primary endpoint of noninferiority for 3-point major adverse cardiovascular events (HR, 0.92), while also showing additional benefits in A1C, weight reduction, renal preservation, and a 16% reduction in all‑cause mortality (HR, 0.84). According to Eli Lilly, a submission, backed by this data, is expected before the close of 2025.
Related Content: Diabetes Dialogue: Tirzepatide and SURPASS-CVOT Topline Results
ENDO 2025 Highlights
Palopegteriparatide Provides Sustained Response in Adults with Hypoparathyroidism
On July 14, 2025, Ascendis Pharma announced positive 3-year results from the phase 3 PaTHway trial examining palopegteriparatide (TransCon PTH) in adults with hypoparathyroidism. Based on data from 82 participants followed through Week 156, the therapy maintained normal albumin-adjusted serum calcium in 88% of patients, eliminated conventional therapy reliance in 96%, and improved mean eGFR by up to 13.98 mL/min/1.73 m² in those with baseline impairment. According to Ascendis Pharma, the findings demonstrate sustained efficacy, kidney function improvement, and quality-of-life benefits across disease etiologies, with no new safety signals observed.
Diabetes Dialogue: GLP-1s, SGLT2s, and Diabetes Barbie at ENDO 2025
In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, recapped highlights from the 2025 Endocrine Society annual meeting and spotlighted the importance of Diabetes Barbie for addressing disease stigma.
Hypercortisolism in Patients with Treatment-Resistant Type 2 Diabetes, with Richard Auchus, MD, PhD
At the ENDO 2025, Richard Auchus, MD, PhD, presented the results of a CATALYST trial analysis investigating the characteristics of patients with difficult-to-treat type 2 diabetes with hypercortisolism. As part of our coverage of ENDO 2025, we sat down with Auchus to learn more about how this might help guide treatment with mifepristone.
Related Content:
